Ask AI
ProCE Banner Activity

CME

The HER2 Horizon: The Next Era of HER2‑Targeted Treatment in GI Cancer

Video

In this on-demand webcast, experts review current standards and emerging evidence for HER2 testing and HER2-directed therapy in advanced gastroesophageal adenocarcinoma and biliary tract cancer, with emphasis on how biomarker results should guide treatment selection and sequencing. Experts also discuss guideline-based HER2 assessment, clinical implications of intratumoral HER2 heterogeneity and loss of HER2 expression after treatment, and the rationale for reassessing HER2 status at progression. Pivotal and emerging clinical trial data for trastuzumab-, zanidatamab-, and trastuzumab deruxtecan–based strategies are summarized, and faculty address how efficacy, PD-L1 status, prior therapy, comorbidities, and toxicity profiles may influence treatment decisions. Practical management of treatment-related toxicities, particularly zanidatamab-associated diarrhea and infusion-related reactions and trastuzumab deruxtecan–associated interstitial lung disease/pneumonitis, is also discussed to support safe implementation of HER2-targeted therapy in clinical practice.

Physicians: Maximum of 1.00 AMA PRA Category 1 Credit

European Learners: 1.00 EBAC® CE Credit

Released: September 08, 2026

Expiration: March 07, 2027

Share

Provided by

Provided by Clinical Care Options, LLC dba Decera Clinical Education

ProCE Banner

Supporters

This activity is supported by an educational grant from Jazz Pharmaceuticals, Inc.

Jazz Pharmaceuticals, Inc.

Target Audience

This activity is intended for medical oncologists and other healthcare professionals involved in the care of patients with gastroesophageal adenocarcinoma and biliary tract cancer. 

Program Learning Goal

The goal of this activity is to improve learners’ knowledge, competence, and confidence in applying biomarker-driven, evidence-based, and patient-centered HER2-directed treatment strategies for patients with gastroesophageal adenocarcinoma and biliary tract cancer.

Learning Objectives

Upon completion of this activity, participants should be able to:

  • Apply guideline-concordant HER2 testing and interpretation strategies for GEA and BTC, including appropriate integration of pathology results with PD-L1 status and broader molecular profiling

  • Critically evaluate newly presented and recently reported clinical trial data in HER2-positive GEA and BTC, distinguishing established standards from investigational approaches

  • Individualize treatment selection and sequencing for patients with HER2-positive GEA and BTC based on disease setting, prior therapy, biomarker profile, comorbidities, toxicity risk, and patient goals

  • Implement proactive monitoring and mitigation strategies for clinically relevant toxicities associated with HER2-directed therapies

  • Identify appropriate patients for referral to clinical trials evaluating novel HER2-directed agents and combinations in GI malignancies

Financial Disclosures

Decera Clinical Education requires instructors, planners, managers, and other individuals who are in a position to control the content of this activity to disclose all financial conflicts of interest (COI) they may have with ineligible companies. All relevant COI are thoroughly vetted and mitigated according to Decera Clinical Education policy. Decera Clinical Education is committed to providing its learners with high-quality CME/CE activities and related materials that promote improvements or quality in healthcare and not a specific proprietary business interest of an ineligible company.

The faculty reported the following relevant financial relationships or relationships to products or devices they have with ineligible companies related to the content of this educational activity:

Primary Author

Michel Ducreux, MD, PhD: consultant/advisor/speaker: Astellas, Bayer,Bristol Myers Squibb, Daiichi Sankyo, Incyte, Jazz, Merck Serono, Revolution Medicines, Takeda.

Geoffrey Ku, MD: consultant/advisor/speaker: Astellas, AstraZeneca, BeOne, Bristol Myers Squibb, Daiichi Sankyo, Gilead, I-Mab/NovaBridge, Jazz, Merck, Oncolys; researcher: Astellas, CARsgen, BeOne, I-Mab/NovaBridge, Jazz, Merck, Oncolys; other financial or material support: Dava Oncology.

The planners and content peer reviewers from Decera Clinical Education do not have any relevant financial relationships to disclose.

Instructions for Credit

Participation in this self-study activity should be completed in approximately 1 hour. To successfully complete this activity and receive credit, participants must follow these steps during the period from September 08, 2026, through March 07, 2027:

  1. Login or Sign Up for an account by clicking at the top of this page.
  2. Read the target audience, learning objectives, and faculty disclosures.
  3. View and study the content in its entirety.
  4. Submit answers to the posttest questions and evaluation questions online.

You must receive a test score of at least 65 and respond to all evaluation questions to receive a certificate. After submitting the evaluation, you may access your online certificate by selecting the certificate link on the confirmation page. Records of all CME/CE activities completed can be found on the "My Certificates" page. There are no costs/fees for this activity.

Format

This program has been made available online.

Disclosure of Unlabeled Use

This educational activity may contain discussion of published and/or investigational uses of agents that are not indicated by the FDA. The planners of this activity do not recommend the use of any agent outside of the labeled indications.

The opinions expressed in the educational activity are those of the faculty and do not necessarily represent the views of the planners. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings.

Additional Disclosures

Participants have an implied responsibility to use the newly acquired information to enhance patient outcomes and their own professional development. The information presented in this activity is not meant to serve as a guideline for patient management. Any procedures, medications, or other courses of diagnosis or treatment discussed or suggested in this activity should not be used by clinicians without evaluation of their patient’s conditions and possible contraindications and/or dangers in use, review of any applicable manufacturer’s product information, and comparison with recommendations of other authorities.

Accreditation

Joint Accreditation Statement

In support of improving patient care, Clinical Care Options, LLC dba Decera Clinical Education is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.

Physician Continuing Medical Education

Clinical Care Options, LLC dba Decera Clinical Education designates this enduring material for a maximum of 1 AMA PRA Category 1 Credit™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

EBAC Accreditation

Clinical Care Options, LLC dba Decera Clinical Education is an EBAC® accredited provider since 2025

This program is accredited by the European Board for Accreditation of Continuing Education for Health Professionals (EBAC®) for 1.0 hour of effective education time.

EBAC® holds an agreement on mutual recognition of substantive equivalency with the US Accreditation Council for CME (ACCME) and the Royal College of Physicians and Surgeons of Canada, respectively.

Through an agreement between the European Board for Accreditation of Continuing Education for Health Professionals (EBAC®) and the American Medical Association, physicians may convert EBAC® External CME credits to AMA PRA Category 1 Credits™. Information on the process to convert EBAC® credit to AMA credit can be found on the AMA website. Other health care professionals may obtain from the AMA a certificate of having participated in an activity eligible for conversion of credit to AMA PRA Category 1 Credit™.

EBAC® is a member of the International Academy for CPD Accreditation (IACPDA), the World Federation for Medical Education (WFME) CPD Recognition Committee, and a partner member of the International Association of Medical Regulatory Authorities (IAMRA).

CME Passport

A logo for a companyDescription automatically generated

The CME credits that physicians earn from this activity will be submitted to ACCME's CME Passport, a free, centralized web application where you can create a personalized account to view, track, and generate transcripts of your reported CME credit. Visit cmepassport.org to create your account.